ViRexx to focus outlay on current pipeline

4 December 2006

Canadian drug developer ViRexx Medical Corp says that it plans to make a 65% reduction in its R&D expenditure by focusing on completing the development of its existing pipeline products. The company said that the refocusing of research priorities would reduce its average monthly spending to less than $900,000.

ViRexx' chief executive, Lorne Tyrrell, said that "the new business model appropriately balances risk and reward within our development priorities." He added that the approach would allow the firm to invest in programs with promising near-term potential.

Specifically, the company will focus on the development of its OvaRex monoclonal antibody product and the Occlusin 500 Device, for prospective launch in the next few years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight